What is the difference between tumor mutational burden as a predictive biomarker for immunotherapy response in MSI-high versus MSS endometrial cancers?

Tumor Mutational Burden in Endometrial Cancer: A Biomarker's Different Role in MSI-H vs. MSS Disease

For patients and oncologists navigating endometrial cancer treatment, biomarkers like tumor mutational burden (TMB) have become central to decision-making, particularly with immunotherapy. A common point of confusion arises from its application across different molecular subtypes. The core difference lies not in the measurement of TMB itself, but in its biological meaning and predictive power when the cancer is microsatellite instability-high (MSI-H) versus microsatellite stable (MSS).

Myth vs. Reality: One Biomarker, Two Contexts

A prevailing myth is that a high TMB score universally guarantees a strong response to immune checkpoint inhibitors (ICIs) like pembrolizumab or dostarlimab. The reality is more nuanced. In MSI-H endometrial cancers, high TMB is a downstream consequence of the underlying DNA mismatch repair deficiency (dMMR). This defect creates a flood of novel mutation-associated neoantigens, making the tumor highly visible to the immune system. Here, TMB is a reliable correlate of a known, powerful predictive mechanism.

In MSS endometrial cancers, the story changes. These tumors are generally immunologically "colder." A high TMB in this context may arise from other mutational processes, like exposure to specific carcinogens or mutations in polymerase genes. While a high TMB can still indicate more neoantigens, the tumor microenvironment in MSS disease often contains additional immunosuppressive barriers. Therefore, TMB alone is a less consistent and generally weaker predictor of ICI response in MSS tumors compared to its near-definitive role in MSI-H disease.

The Data Evidence: Clinical Trials Tell the Story

Clinical trial data solidifies this distinction. The landmark KEYNOTE-158 study, which led to the tissue-agnostic FDA approval of pembrolizumab for TMB-high solid tumors, provides clear evidence. The overall response rate for TMB-high patients was 29%, but this pooled both MSI-H and MSS cancers. When analyzed by subtype, the response rates in MSI-H cancers are consistently higher, often exceeding 50% in endometrial cancer cohorts, while the rates in MSS, TMB-high cancers are more variable and typically lower.

Research indicates that within MSS endometrial cancers, a very high TMB (often defined as ≥20 mutations/megabase) may identify a small subset of patients who could benefit from immunotherapy. However, the predictive threshold is less clear, and responses are not as robust or durable as those seen in MSI-H disease. This has led many clinical researchers to view high TMB in MSS tumors as a potential enabling factor, but one that likely requires the absence of other resistance mechanisms or combination with other therapies to be truly predictive.

Expert Perspective: Integrating Biomarkers in Clinical Practice

From what practitioners in gynecologic oncology report, the diagnostic pathway clarifies the hierarchy. For a new diagnosis of advanced or recurrent endometrial cancer, testing for MSI status or dMMR via immunohistochemistry is a first-line standard. An MSI-H/dMMR result is considered a primary predictive biomarker for immunotherapy, effectively superseding the need for a separate TMB assessment in that context, as the mechanism is established.

"We treat MSI-H status as the definitive biomarker. If a patient is MSI-H, we have high confidence in immunotherapy regardless of the specific TMB number. For MSS tumors, the picture is murkier. A high TMB might encourage us to consider immunotherapy, especially in later lines of therapy, but we counsel patients that the odds of response are lower and we are more likely to look for clinical trial options combining ICIs with other agents," notes a leading academic gynecologic oncologist.

TMB testing becomes more relevant specifically in the MSS population, where it serves as a secondary or exploratory biomarker to help prioritize treatment options when standard therapies are exhausted. This layered approach to biomarker testing—where MSI status is primary and TMB provides supplementary information in MSS cases—is a practical application of the underlying biology. For oncology teams, managing this complex biomarker data, from MSI and TMB to PD-L1 and specific genetic mutations like POLE, requires robust data integration, a service specialized oncology data platforms provide to ensure treatment decisions are based on a complete molecular profile.

Conclusion

The difference in TMB as a biomarker between MSI-H and MSS endometrial cancers is fundamental. In MSI-H disease, high TMB is a hallmark of the causative dMMR mechanism and is a strong, consistent predictor of immunotherapy benefit. In MSS disease, high TMB is a more isolated metric with moderate and variable predictive power, identifying a smaller subset of potential responders. The clinical takeaway is that MSI status remains the dominant and first-test biomarker, with TMB offering additional, context-dependent information, primarily for tailoring approaches in the more challenging MSS setting.

Frequently Asked Questions

If my endometrial cancer is MSI-H but has a "low" TMB score, is immunotherapy still recommended?

Yes, in most cases. MSI-H/dMMR status is the primary predictive biomarker. The underlying biology that causes MSI-H almost invariably leads to a sufficiently high neoantigen burden to make the tumor responsive to immunotherapy, even if the formal TMB score falls near a lower threshold. The clinical trial evidence supporting immunotherapy in MSI-H cancer is based on the MSI status, not the TMB value.

Can a patient with MSS endometrial cancer and a high TMB receive FDA-approved immunotherapy?

It is possible, but the pathway is less straightforward. The tissue-agnostic approval for pembrolizumab in TMB-high (≥10 mut/Mb) solid tumors does apply. However, many insurers require prior therapy, and the expected response rate is lower than for MSI-H cancers. Treatment in this context is often considered after discussing the more modest odds of benefit and exploring potential clinical trials.

How are MSI and TMB testing related? Do I need both tests?

The tests are related but distinct. MSI status is typically determined first via specific molecular PCR tests or by looking for the loss of mismatch repair proteins (dMMR) on immunohistochemistry. TMB is usually measured using next-generation sequencing (NGS) panels. If an NGS panel is performed, it may report both MSI status and TMB. If you are MSI-H from an initial test, a separate TMB test is generally not necessary for treatment decisions. For MSS tumors, the TMB result from an NGS panel becomes the relevant data point.